Syndax Pharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical company advancing innovative cancer therapies.
The company has two commercially approved medicines, Revuforj (revumenib) and Niktimvo (axatilimab-csfr), and a robust slate…
Analysis
Middle-of-the-road
Syndax Pharmaceuticals, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.
Valuation data is not available for this company.
Growth is solid; the safety picture is adequate. The company scores 10/20 on our value-creation score: creating some value.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Mar 202693
100
2026
All-time high
100
Jun 2026
All-time low
93
Mar 2026
Average rank
97
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
84
—
—
—
Price/Earnings
85
—
—
—
Price/Book
95
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
100
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.